Medicine
Insulin Aspart Protamine and Insulin Aspart Mix 70/30 100 IU/mL injectable suspension
Insulin Aspart Protamine and Insulin Aspart Mix 70/30 100 IU/mL injectable suspension is a prescription medicine containing Insulin aspart for subcutaneous use, marketed by Novo Nordisk Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store unused Insulin Aspart Protamine and Insulin Aspart in a refrigerator…
Key facts
- Active ingredient (INN)
- Insulin aspart
- Brand
- Insulin Aspart Protamine and Insulin Aspart Mix 70/30
- Strength
- 100 IU/mL
- Dosage form
- Injectable suspension
- Route
- Subcutaneous
- Packs
- 1 vial, 5 syringes
- Marketing authorisation holder
- Novo Nordisk Pharma
- Manufacturers
- Novo Nordisk PharmaRemedyrepack
- Origin register
- US FDA, United States
- Storage
- Store unused Insulin Aspart Protamine and Insulin Aspart in a refrigerator between 2°C to 8°C (36°F to 46°F). Do not freeze Insulin Aspart Protamine and Insulin Aspart or use Insulin Aspart Protamine and Insulin Aspart if it has been frozen.
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A10AB05 Insulin aspart
- HS code (indicative)
- 3004.31Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 November 2001
- Identifiers
- RxCUI 351297, 847191DailyMed set ID fc94baa4-3606-48bc-a781-9617ab6960ef, 5d9f0e10-edb9-4960-bd62-cf406e75bbe7NDC 73070-203, 70518-3236, 73070-200Application BLA021172
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, glass in 1 carton / 10 mL in 1 vial, glass | 73070-200-11 | Novo Nordisk Pharma | 10 September 2019 |
| 5 syringe, plastic in 1 carton / 3 mL in 1 syringe, plastic | 73070-203-15 | Novo Nordisk Pharma | 10 September 2019 |
| 5 syringe, plastic in 1 carton / 3 mL in 1 syringe, plastic | 70518-3236-0 | Remedyrepack | 28 January 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Insulin aspart 100 IU/mL injectable suspension.
Other strengths and forms of Insulin aspart
Clinical summary
Insulin aspart is an insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. It is available as injection and injectable suspension for subcutaneous and intravenous use. MedsAcross supplies Insulin aspart for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Insulin aspartFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Fiasp prescribing information (Novo Nordisk) · U.S. National Library of Medicine, DailyMed
- Fiasp: European public assessment report (EPAR) · European Medicines Agency
- NovoMix: European public assessment report (EPAR) · European Medicines Agency
Need Insulin Aspart Protamine and Insulin Aspart Mix 70/30 100 IU/mL injectable suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.